EQS-News: Sartorius AG Supervisory Board extends appointment of board member Florian Funck
|
EQS-News: SARTORIUS AG
/ Key word(s): Personnel
Göttingen, Germany | April 24, 2026
Sartorius AG Supervisory Board extends appointment of board member Florian Funck The Supervisory Board of Sartorius AG resolved to extend the appointment of Dr. Florian Funck as Chief Financial Officer (CFO) and member of the Executive Board ahead of schedule to March 31, 2032. Funck (55) studied business administration at the University of Münster, where he also earned his doctorate. He subsequently spent more than two decades with the Haniel Group, most recently serving as CFO from 2011 to 2023. Funck was appointed to the Executive Board of Sartorius in April 2024; in this role, he is responsible for Finance & Controlling, IT & Process, Corporate Compliance, Internal Audit and Corporate Sourcing. In addition, Funck is a member of the Supervisory Board of Vonovia SE and an honorary professor at the University of Münster. The Executive Board of Sartorius AG also comprises Chairman and Chief Executive Officer Dr. Michael Grosse, who oversees Strategy, Human Resources, Corporate Research, Legal Affairs, and Communications & IR, as well as the two Heads of Division Dr. René Fáber (Bioprocess Solutions) and Dr. Alexandra Gatzemeyer (Lab Products & Services). Further Information CV of Florian Funck Financial calendar July 23, 2026 | Publication of half-year results for January to June 2026 October 22, 2026 | Publication of nine-month results January to September 2026 A profile of Sartorius Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.
Visit our newsroom or follow Sartorius on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Additional features: File: Sartorius AG Supervisory Board extends appointment of board member Florian Funck | Media Release File: Sartorius Member of the Executive Board Florian Funck | Photo 2026
24.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SARTORIUS AG |
| Otto-Brenner-Straße 20 | |
| 37079 Göttingen | |
| Germany | |
| Phone: | +49.(0)551-308.0 |
| Fax: | +49.(0)551-308.3289 |
| E-mail: | info@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | DE0007165631, DE0007165607 |
| WKN: | 716563, 716560 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2312068 |
| End of News | EQS News Service |
|
|
2312068 24.04.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 2.335,66 | 3.449,22 | 4.174,70 | 3.395,70 | 3.380,70 | 3.538,10 | 3.805,00 | |
| EBITDA1,2 | 636,70 | 1.134,26 | 1.410,40 | 962,70 | 945,30 | 1.051,60 | 1.165,00 | |
| EBITDA-Margin3 | 27,26 | 32,89 | 33,78 | 28,35 | 27,96 | 29,72 | 30,62 | |
| EBIT1,4 | 456,11 | 903,16 | 1.064,80 | 503,90 | 530,00 | 542,60 | 565,00 | |
| EBIT-Margin5 | 19,53 | 26,18 | 25,51 | 14,84 | 15,68 | 15,34 | 14,85 | |
| Net Profit (Loss)1 | 299,56 | 426,98 | 913,10 | 290,60 | 137,40 | 230,40 | 250,00 | |
| Net-Margin6 | 12,83 | 12,38 | 21,87 | 8,56 | 4,06 | 6,51 | 6,57 | |
| Cashflow1,7 | 511,53 | 865,81 | 734,20 | 853,60 | 976,00 | 837,00 | 860,00 | |
| Earnings per share8 | 4,38 | 8,09 | 9,58 | 4,95 | 5,30 | 4,79 | 5,30 | |
| Dividend per share8 | 0,71 | 1,26 | 1,44 | 0,74 | 0,74 | 0,74 | 1,44 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Sartorius VZ | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 716563 | DE0007165631 | AG | 14.743,87 Mio € | 10.07.1990 | Halten | 9F3FHV2Q+JW |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 36,47 | 40,14 | 0,91 | 50,31 | 6,17 | 19,57 | 4,17 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,74 | 0,74 | 0,74 | 0,34% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.03.2026 | 23.04.2026 | 23.07.2026 | 22.10.2026 | 16.02.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -2,78% | -1,76% | -11,49% | -3,74% | +3.630,61% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
